Anticoagulant therapy: warfarin sensitivity genotyping closer to clinical practice.
van der Zee
Sarina A
SA
The Zena and Michael A. Weiner Cardiovascular Institute and The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Box 1030, Mount Sinai Medical Center, 5th Avenue at 100th Street, New York, NY 10029, USA.
Halperin
Jonathan L
JL
D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D054316:Biomarkers, Pharmacological; D016001:Confidence Intervals; D065729:Cytochrome P-450 CYP2C9; D014644:Genetic Variation; D005838:Genotype; D006470:Hemorrhage / Q000139:chemically induced* / Q000235:genetics; D006801:Humans; D019934:International Normalized Ratio; D006899:Mixed Function Oxygenases / Q000235:genetics; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000009:adverse effects* / Q000627:therapeutic use
D000925:Anticoagulants; D054316:Biomarkers, Pharmacological; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases